Recent upsizing of Attovia Therapeutics’ IPO to $289 million at the $17 top of its range implies a roughly $731 million post-offering market cap, aligning with the company’s Phase 1 pipeline in immune-mediated diseases and strong institutional backing from Goldman Sachs and others. This pricing reflects robust biotech IPO demand in 2026, where 13 prior deals have raised a median exceeding $300 million amid favorable sentiment for clinical-stage assets targeting indications like chronic pruritus. With the Nasdaq listing slated for August 5, 2026—well before the October cutoff—trader consensus remains split between a potential post-debut trading premium pushing toward the $900 million–$1 billion band and lingering execution or market-absorption risks that could keep the closing valuation nearer $600–800 million ranges. Upcoming first-day volume and any early analyst coverage will likely determine which outcome prevails.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於低於 6 億美元 50%
9億至10億美元 50%
2026年10月之前不會上市 38%
6億美元-7億美元 27%
最新
最新
2026-08-05
低於 6 億美元
50%
6億美元-7億美元
27%
7億美元至8億美元
26%
8 億美元 - 9 億美元
26%
9億至10億美元
50%
10億美元以上
26%
2026年10月之前不會上市
38%
低於 6 億美元 50%
9億至10億美元 50%
2026年10月之前不會上市 38%
6億美元-7億美元 27%
最新
最新
2026-08-05
低於 6 億美元
$0 交易量
50%
6億美元-7億美元
$0 交易量
27%
7億美元至8億美元
$0 交易量
26%
8 億美元 - 9 億美元
$0 交易量
26%
9億至10億美元
$0 交易量
50%
10億美元以上
$0 交易量
26%
2026年10月之前不會上市
$0 交易量
38%
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent upsizing of Attovia Therapeutics’ IPO to $289 million at the $17 top of its range implies a roughly $731 million post-offering market cap, aligning with the company’s Phase 1 pipeline in immune-mediated diseases and strong institutional backing from Goldman Sachs and others. This pricing reflects robust biotech IPO demand in 2026, where 13 prior deals have raised a median exceeding $300 million amid favorable sentiment for clinical-stage assets targeting indications like chronic pruritus. With the Nasdaq listing slated for August 5, 2026—well before the October cutoff—trader consensus remains split between a potential post-debut trading premium pushing toward the $900 million–$1 billion band and lingering execution or market-absorption risks that could keep the closing valuation nearer $600–800 million ranges. Upcoming first-day volume and any early analyst coverage will likely determine which outcome prevails.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市場開放時間： Aug 4, 2026, 9:51 PM ET
交易量
$0結束日期
2026-08-05市場開放時間
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent upsizing of Attovia Therapeutics’ IPO to $289 million at the $17 top of its range implies a roughly $731 million post-offering market cap, aligning with the company’s Phase 1 pipeline in immune-mediated diseases and strong institutional backing from Goldman Sachs and others. This pricing reflects robust biotech IPO demand in 2026, where 13 prior deals have raised a median exceeding $300 million amid favorable sentiment for clinical-stage assets targeting indications like chronic pruritus. With the Nasdaq listing slated for August 5, 2026—well before the October cutoff—trader consensus remains split between a potential post-debut trading premium pushing toward the $900 million–$1 billion band and lingering execution or market-absorption risks that could keep the closing valuation nearer $600–800 million ranges. Upcoming first-day volume and any early analyst coverage will likely determine which outcome prevails.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$0結束日期
2026-08-05市場開放時間
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...Recent upsizing of Attovia Therapeutics’ IPO to $289 million at the $17 top of its range implies a roughly $731 million post-offering market cap, aligning with the company’s Phase 1 pipeline in immune-mediated diseases and strong institutional backing from Goldman Sachs and others. This pricing reflects robust biotech IPO demand in 2026, where 13 prior deals have raised a median exceeding $300 million amid favorable sentiment for clinical-stage assets targeting indications like chronic pruritus. With the Nasdaq listing slated for August 5, 2026—well before the October cutoff—trader consensus remains split between a potential post-debut trading premium pushing toward the $900 million–$1 billion band and lingering execution or market-absorption risks that could keep the closing valuation nearer $600–800 million ranges. Upcoming first-day volume and any early analyst coverage will likely determine which outcome prevails.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions